含粒细胞-巨噬细胞集落刺激因子的培养基用于囊胚复苏培养:随机对照试验研究方案(GSET研究)
本研究为多中心、随机、平行组、活性对照、单盲试验,计划招募750例符合标准的患者,1:1随机分为含GM-CSF培养基组(试验组)与不含GM-CSF培养基组(对照组),冻融囊胚在复苏培养3-7小时后进行移植,主要结局为活产。该研究旨在前瞻性评估含GM-CSF的囊胚复苏培养能否提高冻融囊胚移植后的活产率。
要点
- 含GM-CSF培养基用于冻融囊胚复苏培养可能提高活产率,需前瞻性验证。
- 本研究为多中心随机单盲活性对照试验,计划样本量750例。
- 主要结局为活产,次要结局包括胚胎移植结局及围产期和新生儿安全结局。
核心结论
- 研究将前瞻性评估含GM-CSF培养基用于冻融囊胚复苏培养能否提高活产率。
- 这是首个大规模前瞻性研究,旨在为GM-CSF培养基在冻融囊胚移植中的效率提供证据。
研究设计与样本
- 多中心、随机、平行组、活性对照、单盲试验,招募目标为750例符合标准的参与者。
- 入组患者按1:1随机分为含GM-CSF培养基组(试验组)或不含GM-CSF培养基组(对照组)。
关键数值与推荐
- 干预为冻融囊胚在含GM-CSF培养基(试验组)或不含GM-CSF培养基(对照组)中复苏培养3-7小时后进行移植。
- 主要结局为活产;次要疗效终点包括胚胎移植结局;安全性终点包括围产期和新生儿结局。
- 试验注册于日本临床试验注册中心jRCT1040240159,注册日期为2025年1月6日。
临床怎么用
- 若研究证实有效,含GM-CSF培养基复苏培养可能成为冻融囊胚移植前的常规干预以改善活产率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the number of frozen-thawed blastocysts transfer is increasing worldwide, the live birth rate following blastocyst transfer using assisted reproductive technology remains at 30-60%. Thus, improving the pregnancy rate per transfer is an urgent issue. In a previous retrospective study, we evaluated the use of granulocyte-macrophage colony-stimulating factor (GM-CSF)-containing medium for recovery culture to improve the outcomes of frozen-thawed blastocyst transfers. The results demonstrated that the live birth rates increased by approximately 10% following recovery culture in the GM-CSF-containing culture medium. This study aims to prospectively evaluate whether GM-CSF-containing blastocyst recovery culture following thawing increases live birth. METHODS: This is a multicenter, randomized, parallel-group, active-controlled, single-blind trial. The recruitment target is 750 participants meeting the criteria. Enrolled patients are randomized 1:1 to the GM-CSF-containing culture medium group (test group) or the non-GM-CSF-containing culture medium group (control group). The blastocyst recovery culture after warming was defined as an intervention in this study; frozen-thawed blastocysts will be cultured for 3-7 h in GM-CSF-containing medium (test group) or medium without GM-CSF (control group) followed by blastocyst transfer. The primary outcome will be live birth. We will also evaluate embryo transfer outcomes as secondary efficacy endpoints and evaluate perinatal and neonatal outcomes as a safety endpoint. DISCUSSION: This is the first large-scale prospective study to investigate the efficacy of a GM-CSF-containing medium for frozen-thawed blastocyst transfer. The study findings will provide evidence regarding the efficiency of GM-CSF-containing medium for blastocyst recovery culture after warming. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCT1040240159. Registered on January 6, 2025.
引用
- Kobayashi T, Higuchi K, Okabe-Kinoshita M, et al. Granulocyte-macrophage colony-stimulating factor-containing medium for blastocyst recovery culture: study protocol for a randomized controlled trial (GSET-study). Trials. 2026. PMID: 41827043. doi:10.1186/s13063-026-09634-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。